<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04326829</url>
  </required_header>
  <id_info>
    <org_study_id>QL1604-201</org_study_id>
    <nct_id>NCT04326829</nct_id>
  </id_info>
  <brief_title>QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors</brief_title>
  <official_title>A Single-arm, Multi-center, Phase Ⅱ Clinical Study to Evaluate Efficacy and Safety of QL1604 Monotherapy for the Treatment of Unresectable or Metastatic Mismatch Repair Deficient (dMMR) or Microsatellite Instability-high (MSI-H) Solid Tumors That Failed to Respond to Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, patients with previously-treated locally-advanced or metastatic mismatched&#xD;
      repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC)&#xD;
      and other solid tumors will be treated with QL1604 monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Objective response rate (assessed by independent radiological review committee (IRRC) per RECIST Version 1.1 and iRECIST)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Objective response rate (assessed by the investigators per RECIST Version 1.1 and iRECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month PFS rate</measure>
    <time_frame>the proportion of subjects who have time interval over 6 months between the first dose and disease progression or death</time_frame>
    <description>6-month progression-free survival (PFS) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month OS rate</measure>
    <time_frame>from the date of first dose until the date of 6-month</time_frame>
    <description>6-month overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier), assessed up to 2 years</time_frame>
    <description>Progression-free survival (assessed by independent radiological review committee (IRRC) per RECIST v1.1 and iRECIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier), assessed up to 2 years</time_frame>
    <description>Progression-free survival (assessed by the investigators per RECIST v1.1 and iRECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from the date of first dose until the date of death from any cause， assessed up to 2 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>from the date when CR or PR (whichever recorded earlier) is firstly achieved until the date when disease progression or death is firstly recorded (whichever occurs earlier), assessed up to 2 years</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Advanced Malignant Tumor</condition>
  <arm_group>
    <arm_group_label>QL1604 Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QL1604</intervention_name>
    <description>QL1604, IV infusion</description>
    <arm_group_label>QL1604 Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Volunteer to participate in this clinical study; completely understand and know this&#xD;
             study as well as sign the informed consent form (ICF);&#xD;
&#xD;
          2. Age ≥ 18 years and ≤ 80 years when ICF is signed;&#xD;
&#xD;
          3. Histologically confirmed locally advanced or metastatic dMMR or MSI-H status&#xD;
             colorectal carcinoma or other malignant solid tumors;&#xD;
&#xD;
          4. At least one measureable lesion as defined per RECIST Version (v) 1.1 ;&#xD;
&#xD;
          5. Subjects who have disease progression or intolerable reactions after the currently&#xD;
             available standard anti-cancer treatment previously received or refused prior cancer&#xD;
             therapy regimen(s) ;&#xD;
&#xD;
          6. Subjects must provide tumor tissues and blood samples for the determination of MSI,&#xD;
             tumor mutational burden (TMB), PD-L1 expression level;&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group performance status of 0 or 1;&#xD;
&#xD;
          8. Life expectancy of greater than 12 weeks;&#xD;
&#xD;
          9. Adequate hematologic and organ function;&#xD;
&#xD;
         10. Female subjects who are not pregnant or breastfeeding&#xD;
&#xD;
         11. Male and female subjects able to have children must agree to use highly effective&#xD;
             method of contraception throughout the study and for at least 120 days after last&#xD;
             dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to any monoclonal antibody, QL1604 and/or any of its&#xD;
             excipients;&#xD;
&#xD;
          2. Subjects with known central nervous system (CNS) metastasis;&#xD;
&#xD;
          3. Active autoimmune disease that has required systemic treatment in past 2 years,&#xD;
             replacement therapy is acceptable;&#xD;
&#xD;
          4. Subjects with major cardiovascular and cerebrovascular diseases;&#xD;
&#xD;
          5. Subjects with uncontrollable pleural effusion, pericardial effusion or ascites;&#xD;
&#xD;
          6. Any condition that required systemic treatment with either corticosteroids (&gt; 10 mg&#xD;
             daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days&#xD;
             before the first dose of study drug;&#xD;
&#xD;
          7. Subjects who have received surgery, radiotherapy, chemotherapy, targeted therapy,&#xD;
             other anti-tumor treatments, or participating in other clinical studies is less than 4&#xD;
             weeks before the first administration of investigational product;&#xD;
&#xD;
          8. Subjects who have not recovered to CTC AE Grade 1 or better from related side effects&#xD;
             of any prior antineoplastic therapy;&#xD;
&#xD;
          9. Received a live vaccine within 30 days of planned start of study medication;&#xD;
&#xD;
         10. Infection with human immunodeficiency virus (HIV), HAV, HBV and HCV;&#xD;
&#xD;
         11. Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-ligand 1&#xD;
             (anti-PD-L1), anti-PD-L2 agent, cytotoxic lymphocyte associated protein-4 (CTLA-4),&#xD;
             OX-40, CD137;&#xD;
&#xD;
         12. Known psychiatric or substance abuse disorders that would interfere with the&#xD;
             requirements of the study;&#xD;
&#xD;
         13. History or current evidence of any condition, therapy, or laboratory abnormality, that&#xD;
             might confound the results of the trial, or interfere with the participant's&#xD;
             participation for the full duration of the study, or investigators/sponsor consider&#xD;
             the subjects are not suitable for this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shunjiang Yu, CMO</last_name>
    <phone>0531-83129659</phone>
    <email>shunjiang.yu@qilu-pharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weijian Guo, Professor</last_name>
    <phone>021-64175590</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>2000 32</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weijian Guo, Professor</last_name>
      <phone>021-64175590</phone>
    </contact>
    <investigator>
      <last_name>Weijian Guo, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Feng Bi, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

